Coagulation Modifier Drugs (final)
Principles of Hemostasis and the Coagulation Cascade
Hemostasis refers to any physiological process that stops bleeding.
Coagulation is a specific form of hemostasis that results from the physiological clotting of blood.
It involves a complex relationship between substances that promote clot formation and those that either inhibit coagulation or dissolve a formed clot.
Thrombus is the technical term for a blood clot.
Embolus is a thrombus that has detached and is moving through blood vessels.
The Coagulation Cascade
Each activated factor in the cascade serves as a catalyst to amplify the subsequent reaction.
The end result of this process is the production of fibrin, which is a clot-forming substance.
The cascade is divided into the intrinsic pathway and the extrinsic pathway.
Extrinsic Pathway: Triggered by tissue trauma. It involves Factor becoming Activated . Along with Tissue Factor (Factor ) and Calcium (), it leads to the activation of Factor .
Intrinsic Pathway: Triggered by blood trauma or contact with collagen. It involves a sequence: Factor . Factor works with Factor , platelets, and to activate Factor .
Common Pathway: Activated Factor () works with Factor , platelets, and to convert Prothrombin (Factor ) into Thrombin (Factor ). Thrombin then converts Fibrinogen (Factor ) into soluble fibrin, which is stabilized into insoluble fibrin by Activated Factor ().
Vitamin K-Dependent Clotting Factors: Factors , , , and require Vitamin K for synthesis in the liver.
Mechanisms and Biological Systems of Fibrinolysis
Fibrinolytic System: This system initiates the breakdown of clots and serves as a balance to the clotting process to prevent excessive formation.
Fibrinolysis: The specific mechanism by which formed thrombi are lysed (broken down) to prevent the blockage of blood vessels.
Plasminogen: A circulating protein that binds to the fibrin within a clot.
Plasmin: When plasminogen binds to fibrin, it is converted into plasmin. Plasmin is an enzymatic protein that breaks down the fibrin thrombus into fibrin degradation products.
This enzymatic action keeps the thrombus localized, preventing it from becoming a dangerous embolus.
Classification of Coagulation Modifier Drugs
Anticoagulants: Also known as antithrombotic drugs. They inhibit the action or formation of clotting factors to prevent clot formation. They have no direct effect on clots that have already formed.
Antiplatelet Drugs: These inhibit platelet aggregation to prevent the formation of platelet plugs.
Hemorheological Drugs: These alter platelet function without completely preventing the platelets from working.
Thrombolytic Drugs: These drugs lyse (break down) existing clots that have already formed.
Antifibrinolytic (Hemostatic) Drugs: These promote blood coagulation.
Pharmacology and Administration of Heparins
Mechanism of Action: Heparins inhibit clotting factors (Thrombin), , and . Factors and are also inactivated, though they play a less significant role.
Unfractionated Heparin ("Heparin"):
A natural anticoagulant obtained from the lungs or intestinal mucosa of pigs.
Available as Heparin Sodium in concentrations ranging from to .
Requires frequent laboratory monitoring using activated Partial Thromboplastin Time (aPTT).
Monitoring occurs every hours until a therapeutic effect is established.
For DVT prophylaxis, a standard dose is subcutaneously to times daily. In this prophylactic setting, aPTT monitoring is generally not required.
Low-Molecular-Weight Heparins (LMWHs):
Synthetic drugs with a smaller molecular structure compared to unfractionated heparin.
Provide a more predictable anticoagulant response.
Frequent laboratory monitoring of aPTT is not required.
Examples:
enoxaparin (Lovenox)
dalteparin (Fragmin)
nadroparin calcium (Fraxiparine)
tinzaparin sodium (Innohep)
Adverse Effects of Heparin:
Bleeding.
Heparin-Induced Thrombocytopenia (HIT):
Type I HIT: Characterized by a gradual reduction in platelets. Heparin therapy can usually be continued.
Type II HIT: Characterized by an acute fall in platelet count (more than reduction from baseline). Heparin therapy must be discontinued immediately. Incidence ranges from to of patients and is more common with unfractionated heparin than LMWH. Thrombosis in the presence of HIT can be fatal.
Treatment for HIT: Thrombin inhibitors such as bivalirudin and argatroban.
Toxicity Management:
Symptoms of toxicity include hematuria, melena, petechiae, ecchymoses, and bleeding from the gums or mucous membranes.
The drug must be stopped immediately.
Antidote: Protamine sulphate IV.
of protamine sulphate can reverse the effects of of heparin.
of protamine sulphate is given for each milligram of LMWH administered.
Warfarin (Coumadin) Therapy and Monitoring
Mechanism of Action: Warfarin is the most commonly prescribed oral anticoagulant. It inhibits the synthesis of Vitamin K by bacteria in the gastrointestinal tract. This, in turn, inhibits the production of Vitamin K-dependent clotting factors (, , , and ) in the liver.
Monitoring Parameters:
Prothrombin Time (PT)
International Normalized Ratio (INR)
A normal INR for a person not on warfarin is to .
A therapeutic INR for a person on warfarin is typically between and .
Adverse Effects: Bleeding, lethargy, muscle pain, skin necrosis, and "purple toes" syndrome.
Toxicity Management:
Discontinue warfarin.
Antidote: Vitamin K1 (phytonadione). High doses () given intravenously can reverse anticoagulation within .
Giving Vitamin K can cause warfarin resistance for up to days afterward.
For severe bleeding, transfusions of human plasma or clotting factor concentrates may be necessary.
Key Considerations: Maintenance doses are determined by INR. Clinicians must consider the patient's age and variations in specific genes such as and .
Direct-Acting Anticoagulants
Antithrombin Medications: These inhibit Thrombin (Factor ).
Natural: Human antithrombin III (Thrombate).
Synthetic: Lepirudin (Refludan), argatroban (Argatroban), bivalirudin (Angiomax), and dabigatran (Pradaxa).
Direct Acting Xa Inhibitors: These target Factor specifically.
Examples: Fondaparinux (Arixtra), rivaroxaban (Xarelto), and apixaban (Eliquis).
Direct Thrombin Inhibitors:
Example: Dabigatran.
Indications and Contraindications for Anticoagulants
Indications: Anticoagulants are used prophylactically to prevent clot formation and emboli in high-risk settings, including:
Myocardial infarction,
Unstable angina,
b
Mechanical heart valves,
Major orthopedic surgery,
Prolonged immobility.
Contraindications:
Known drug allergy.
Acute bleeding processes or a high risk of acute bleeding.
Pregnancy: Warfarin is strongly contraindicated.
Epidural Catheters: LMWHs are contraindicated in patients with an indwelling epidural catheter due to the risk of an epidural hematoma.
Interactions: Anticoagulant interactions are profound and complex. They often involve enzyme inhibition of metabolism, displacement from protein-binding sites, decreased Vitamin K synthesis/absorption in the large intestine, and alterations in platelet activity.
Antiplatelet and Thrombolytic Drugs
Antiplatelet Drugs:
Mechanism: Prevent platelet adhesion and aggregation.
Examples: Aspirin, clopidogrel bisulfate (Plavix), prasugrel (Effient), treprostinil (Remodulin), abciximab (ReoPro), eptifibatide (Integrilin), tirofiban (Aggrastat), anagrelide hydrochloride (Agrylin), and dipyridamole (Aggrenox, Persantine).
Cyclooxygenase Pathway: Platelets use cyclooxygenase to produce Thromboxane A2 (), which causes vasoconstriction and platelet aggregation. Aspirin inhibits this pathway. Blood vessel walls use the same pathway to produce prostacyclin, which causes dilation and inhibits aggregation.
Thrombolytic Drugs:
Mechanism: Activate the fibrinolytic system by converting plasminogen to plasmin, which then lyses (breaks down) the thrombus quickly. This mimics the body's natural clot destruction process.
Current Examples: Alteplase (Activase), tenecteplase (TNKase).
Older Examples: Streptokinase, urokinase.
Indications: Acute myocardial infarction, arterial thrombolysis, deep vein thrombosis (DVT), occlusion of shunts or catheters, pulmonary embolism, and acute ischemic stroke.
Adverse Effects: Internal, intracranial, or superficial bleeding; nausea, vomiting, hypotension, hypersensitivity, anaphylactoid reactions, and cardiac dysrhythmias.
Antifibrinolytic Drugs
Mechanism of Action: These drugs prevent the lysis of fibrin, thereby promoting clot formation.
Indications: Prevention and treatment of excessive bleeding caused by hyperfibrinolysis or surgical complications. They are also used to treat Hemophilia A or Type I von Willebrand's disease (specifically desmopressin).
Examples:
aprotinin (Artiss, Trasylol)
tranexamic acid (Cyklokapron)
desmopressin acetate (DDAVP)
Adverse Effects: Generally uncommon and mild. Rare reports of thrombotic events. Other effects include dysrhythmia, orthostatic hypotension, bradycardia, headache, dizziness, fatigue, hallucinations, convulsions, and GI distress.
Comprehensive Nursing Implications
General Assessment: Check patient history, medication history, allergies, contraindications, baseline vital signs, laboratory values, and history of abnormal bleeding conditions.
Heparin Administration:
Intravenous doses are usually double-checked with a second nurse.
Subcutaneous doses must be given in deep subcutaneous fat, not intramuscularly.
Rotate injection sites.
Do not administer within of the umbilicus, abdominal incisions, open wounds, scars, drainage tubes, stomas, or areas of bruising/oozing.
Do not aspirate the injection or massage the site, as this may cause hematoma formation.
Anticoagulant effects of IV heparin are immediate; monitor aPTT daily.
LMWH Administration: Given subcutaneously in the abdomen; rotate sites. Protamine sulphate is the antidote.
Warfarin Administration:
Often started while the patient is still on heparin until PT/INR reaches therapeutic levels (crossover or bridge therapy).
Full effect takes several days.
Thrombolytic Administration: Follow strict manufacturer guidelines for preparation. Monitor IV sites for bleeding, redness, or pain. Watch for internal bleeding signs: decreased blood pressure, restlessness, and increased pulse.
Patient Education and Dietary Interactions
Education Topics: Importance of regular lab testing, signs of abnormal bleeding, and measures to prevent bruising or tissue injury.
Safety: Patients should wear a medical alert bracelet.
Dietary Restrictions: Patients on warfarin must maintain a consistent intake or avoid foods very high in Vitamin K, such as tomatoes and dark leafy green vegetables.
Natural Health Products: Consult a physician before using herbals, as many increase bleeding risk:
Capsicum pepper
Garlic
Ginger
Ginkgo
St. John's wort
Feverfew
Questions and Discussion
Question: A patient is receiving an IV infusion of heparin and was started on warfarin therapy the night before. Which statement is most correct?
Response: The heparin provides anticoagulation until therapeutic levels of warfarin are reached.
Question: A patient is receiving an IV infusion of a thrombolytic drug for acute myocardial infarction. The nurse notices a slight amount of bleeding from a recent lab draw site in the antecubital area. What is the first action?
Response: Apply pressure to the site with a gauze pad.
Question: A 75-year-old man on warfarin and an antidysrhythmic falls and hits his head, resulting in a small scalp lump but no external bleeding. What is the main concern?
Response: He needs to be examined for possible internal bleeding relating to the fall.
Question: A 72-year-old woman takes a multivitamin with ginkgo and is recommended to start low-dose aspirin for TIAs. What is the concern?
Response: Increased risk of bleeding because of the ginkgo.
Case Study: Conversion from Heparin to Warfarin
Question 1: What are the considerations for converting IV heparin to oral warfarin?
Answer: Overlap therapy of IV heparin and warfarin for to days.
Question 2: Which lab result determines the next dose of warfarin during conversion?
Answer: PT/INR.
Question 3: What recommendation is part of dietary teaching for warfarin?
Answer: Limit intake of tomatoes.
Question 4: If the patient takes too much warfarin and is admitted with bleeding, which drug is anticipated?
Transcript Answer Provided: tenecteplase (TNKase). [Note: Standard clinical practice indicates Vitamin K for warfarin toxicity].